Genomics doesn't merely have massive potential, it's the backbone of research in cancer, even if the diagnostics are slimmed down to simple PCR tests or to even

Genomics doesn't merely have massive potential, it's the backbone of research in cancer, even if the diagnostics are slimmed down to simple PCR tests or to even antibody staining on a slide, or to assigning drugs. In some of the big cancers, sequencing is even a primary diagnostic: * breast cancer: gene expression signatures are standard for determining the necessity of chemo * colon: blood based sequencing for KRAS mutation is extremely common * lung: matching kinase inhibitors to EGFR mutations is essential for therapy * all solid tumors: tumor mutation burden is a companion diagnostic for the major immune checkpoint therapies that have revolutionized treatment over the past decade. I know of almost no cancer that has not had massive changes in treatment, due to accelerated research possibly only through extensive use of genomics.